This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Why Is United Therapeutics (UTHR) Up 5% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Zacks.com featured highlights include: SpartanNash, BG Foods, Regeneron, Vipshop and United Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: SpartanNash, BG Foods, Regeneron, Vipshop and United Therapeutics
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters. Stock down.
United Therapeutics (UTHR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.40% and 2.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Stock Moves -0.98%: What You Should Know
by Zacks Equity Research
In the latest trading session, United Therapeutics (UTHR) closed at $93.90, marking a -0.98% move from the previous day.
United Therapeutics (UTHR) Down 8.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is United Therapeutics (UTHR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (UTHR) Outperforming Other Medical Stocks This Year?
Is United Therapeutics (UTHR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (UTHR) Outperforming Other Medical Stocks This Year?
Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q4 Loss
by Zacks Equity Research
Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.
Zacks.com featured highlights include: McKesson, United Therapeutics, Virtusa and Cardinal Health
by Zacks Equity Research
Zacks.com featured highlights include: McKesson, United Therapeutics, Virtusa and Cardinal Health
United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
by Zacks Equity Research
United Therapeutics (UTHR) misses fourth-quarter estimates on both fronts. Stock declines in response.
Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the fourth quarter of 2019 while revenues beat estimates.
4 Finest Value Stocks Based on Discounted PEG
by Urmimala Biswas
A lower PEG ratio, preferably less than 1, indicates both undervaluation and solid future growth potential of a stock.
Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats fourth-quarter 2019 earnings and revenue estimates. It issues guidance for 2020.
United Therapeutics (UTHR) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -51.42% and -11.10%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will United Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in United Therapeutics.
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y
by Zacks Equity Research
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.